Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma

Divaya Bhutani, Jeffrey A Zonder Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA Abstract: The development of proteasome inhibitors has been a major advance in therapy of multiple myeloma, accounting, in part, for the significant increase in the s...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Bhutani D, Zonder JA
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://doaj.org/article/3d0a108b5d134eb4907426eb0441eb80
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!